Stock comparison
Haemonetics
Madrigal Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
MDGL
Madrigal Pharmaceuticals
Market cap
$11.93B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | MDGL | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 26F | HAE |
| Benjamin Graham | 85A | 60D | HAE |
| Philip Fisher | 60C | 33F | HAE |
| Peter Lynch | 54C | 6F | HAE |
| Joel Greenblatt | 31F | 2F | HAE |
| Charlie Munger | 54D | 33F | HAE |
| Terry Smith | 55D | 27F | HAE |
Side-by-side metrics
| Metric | HAE | MDGL |
|---|---|---|
| Market cap | $2.98B | $11.93B |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | - |
| ROIC (TTM) | 8.37% | -35.2% |
| Gross margin | 55.74% | 93.07% |
| Net margin | 7.29% | -27.32% |
| Revenue CAGR 5y | 7.65% | - |
| EPS CAGR 5y | 24.62% | -4.88% |
| Debt / Equity | 1.5x | 0.6x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Net margin7.29%vs -27.32%+127%
- ROIC (TTM)8.37%vs -35.2%+124%
- EPS CAGR 5y24.62%vs -4.88%+120%
MDGL leads on
- P/E (TTM)-vs 24.8x+151%
- EV/EBIT-vs 14.1x+135%
- Market cap$11.93Bvs $2.98B+75%
- Debt / Equity0.6xvs 1.5x+58%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.